Investigational drug · Phase 3
and dexamethasone
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for AL Amyloidosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3,826
Any phase or sponsor naming "and dexamethasone"
First trial start
2020
Aug 25, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "and dexamethasone", any sponsor or status.
Conditions studied
As listed on its trial records.
- AL Amyloidosis
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "and dexamethasone" as an intervention, largest first.
Joon Young ChoiAcademic, hospital or other
NCT05750797 · 800,000 participants (planned) · Start Mar 1, 2023 · Primary completion Dec 2023
Drug: Oral corticosteroids · For: Asthma; Corticosteroid
Sites: Incheon, South Korea
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
Aetion, Inc.Academic, hospital or other
NCT04926571 · 14,105 participants · Start Apr 1, 2020 · Primary completion Aug 27, 2021
Drug: Dexamethasone Oral · For: Coronavirus
Sites: New York, New York
- The Effect of Cataract Surgery on Sleep QualityPivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT02593669 · 10,000 participants (planned) · Start Jan 2016 · Primary completion Dec 2018
Drug: Subconjunctival dexamethasone and general anesthesia; Viscoelastic materials · For: Cataract; Sleep
Sites: Guangzhou, China
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- Therapeutics for Moderate and Severe DenguePivotal-lookingNot yet recruiting
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT07543458 · 8,800 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2030
Drug: Placebo; Dexamethasone and 2 more · For: Dengue; Severe Dengue; Mosquito-Borne Diseases and 5 more
Sites: Chittagong, Bangladesh; Dhaka, Bangladesh; São Paulo, Brazil · 18 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaPivotal-lookingRecruiting
Mats HeymanAcademic, hospital or other
NCT04307576 · 6,430 participants (planned) · Start Jul 13, 2020 · Primary completion Jun 2033
Drug: Omitted Doxorubicin; Omitted Vincristine+Dexamethasone pulses and 4 more · For: Leukemia, Acute Lymphoblastic
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 137 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Immunoaffinity functionalisation of coated blades for fast, specific and sensitive extraction and analysis of veterinary medicine.
Jager J, Rasker S, Beij E, et al. · Talanta 2027
- Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.
Tan A, Liu J, Chen X, et al. · Hematology 2026
- Pain management after major oncological breast surgery: an updated systematic review and procedure specific postoperative pain management (PROSPECT) recommendations.
Desai N, Dirzu DS, Zolger D, et al. · Anaesthesia 2026
- Implantable starch-based extrudates for controlled release of corticosteroids.
Lemos PVF, Kunert JM, Trutschel ML, et al. · Int J Pharm X 2026
- Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study.
Yin J, Yu S, Wu H, et al. · Ann Med 2026
- Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia.
Reardon B, Kerridge I, Armytage T · Asia Pac J Clin Oncol 2026
Also in development for AL Amyloidosis
- AnselamimabCAEL-101Phase 32 trials
AstraZeneca · AL Amyloidosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.